Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer

Cancer Discovery

Volumn 2, Issue 11, 2012, Pages 995-1003

  Miyamoto, David T ^a   Lee, Richard J ^a   Stott, Shannon L ^a   Ting, David T ^a   Wittner, Ben S ^a   Ulman, Matthew ^a   Smas, Malgorzata E ^a   Lord, Jenna B ^a   Brannigan, Brian W ^a   Trautwein, Julie ^a   Bander, Neil H ^b   Wu, Chin Lee ^a   Sequist, Lecia V ^a   Smith, Matthew R ^a   Ramaswamy, Sridhar ^a   Toner, Mehmet ^a   Maheswaran, Shyamala ^a   Haber, Daniel A ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; BICALUTAMIDE; EPITHELIAL CELL ADHESION MOLECULE; KETOCONAZOLE; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; METASTASIS; OVERALL SURVIVAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84870050058     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0222     Document Type: Article

References (24)

1. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-8261.
2. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27: 36-41.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
4. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
5. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
6. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra3.
7. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010; 107: 18392-18397.
8. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011; 108: 9578-9582.
9. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-7058.
10. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, et al. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009; 55: 765-773
11. Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, et al. Functional characterization of circulating tumor cells with a prostatecancer- specific microfluidic device. PLoS ONE 2012; 7: e35976.
12. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
13. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, et al. Effects of abiraterone acetate on androgen signaling in castrateresistant prostate cancer in bone. J Clin Oncol 2012; 30: 637-643.
14. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-6029.
15. Mendiratta P, Mostaghel E, Guinney J, Tewari AK, Porrello A, Barry WT, et al. Genomic strategy for targeting therapy in castrationresistant prostate cancer. J Clin Oncol 2009; 27: 2022-2029.
16. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-406.
17. Brown RS, Edwards J, Dogan A, Payne H, Harland SJ, Bartlett JM, et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 2002; 198: 237-244.
18. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. A ndrogen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
19. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011; 20: 457-471.
20. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-586.
21. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011; 71: 6503-6513.
22. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov 2012; 2: 320-327.
23. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
24. Text-ToFCS version 1.2.1. Available from: http://offsite.treestar.com/downloads/utilities/TextToFCS_documentation.